



PRESS RELEASE

Chassieu, 10 June 2020

**ORDINARY AND EXTRAORDINARY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 24 2020
MODALITIES THROUGH WHICH THE PREPARATORY DOCUMENTS WILL BE MADE AVAILABLE**

The General Meeting of Amoéba shareholders, convened on May 28, 2020 at 10 a.m. at the Company's registered office, did not reach the quorum required to vote on the ordinary and extraordinary resolutions.

Consequently, a new Ordinary and Extraordinary Shareholders' Meeting will be held on second call on:

**Wednesday 24 June 2020 – 10 am
at the company registered office - 38 Avenue des Frères Montgolfier- 69680 CHASSIEU**

for the purpose of ruling on the same agenda as the first convocation notice, published in the Bulletin des Annonces Légales Obligatoires (BALO) of 13 May 2020.

The notice of the second convocation including the agenda was published in the Bulletin des Annonces légales Obligatoires (BALO) of June 10, 2020. The terms and conditions of participation and voting at the Meeting are set out in this notice.

Disclaimer

In the context of the coronavirus epidemic (COVID-19), traffic restrictions and containment measures imposed by public authorities, the Board of Directors decided, in accordance with the provisions of Ordinance No. 2020-321 of March 25, 2020 and Decree No. 2020-418 of April 10, 2020, that the Annual General Meeting of AMOEBA on Wednesday, June 24, 2020, will exceptionally be held behind closed doors, without the presence of shareholders, at the Company's registered office.

Under these conditions, shareholders are invited to participate in the Shareholders' Meeting by using the postal voting form or by giving a proxy to the Chairman.

The procedures for holding the Shareholders' Meeting may change depending on health and/or legal requirements. Shareholders are invited to regularly consult the section dedicated to the Shareholders' Meeting on the Company's website <http://www.amoeba-biocide.com/fr/informations-reglementaires-et-documents-financiers>.

The results of the votes on the resolutions will be posted on the Company's website.

The documents stipulated by article R.225-83 of the French commercial code are available to shareholders from the moment that the assembly is convened, in line with the applicable regulatory requirements:



- Any named shareholder can, until the fifth day (inclusive) before the assembly, ask the company to send them these documents. For holders of bearer shares, this right can only be exercised upon presentation of a statement of participation in the accounts of bearer shares held by the authorised intermediary;
- Any shareholder can consult these documents at the company's headquarters during the 15 days preceding the date of the assembly.

NEED MORE INFORMATION?

Find all the information you need to vote by post or give proxy to the Chairman on our dedicated page:

<http://www.amoeba-biocide.com/fr/assemblee-generale-du-24-juin-2020>

Download :

[le bulletin de vote par correspondance \(the postal voting\)](#)

[le guide du vote par correspondance \(the guide to voting by correspondence\)](#)

We are at your disposal to provide you with any additional information on voting procedures by calling+ 33 (0)1 53 65 68 68 or by email at amoeba@calyptus.net



About AMOÉBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn ⁽¹⁾ on a global chemical biocide market for water treatment, evaluated at €21Bn ⁽²⁾ and on the biocontrol market for plant protection estimated globally at €1.6Bn ⁽⁴⁾. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million ⁽³⁾ in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE

General Manager

+33 (0)4 26 69 16 00

valerie.filiatre@amoeba-biocide.com

Investors and Media Relations

Grégory BOSSON / Mathieu CALLEUX

Agence Calyptus

+33(0)1 53 65 37 90

gregory.bosson@calyptus.net